Daniela Žáčková

1971 -

educated at: Masaryk University

occupation: pedagogue, researcher

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 29

Date

Title

Authors

2024-02

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

Kateřina Machová Poláková, Václava Polívková, Nikola Curik, Alice Fabarius, Hana Klamová, Birgit Spiess, Edgar Faber, Daniela Žáčková
2022-07

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Kateřina Machová Poláková, Václava Polívková, Hana Klamová, Daniela Žáčková
2020-02-09

Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia

Marianna Romzova, Dagmar Smitalova, Martin Culen, Daniela Žáčková
2020-05-29

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Kateřina Machová Poláková, Ingmar Glauche, Ingo Roeder, Nicholas Cross, Hana Klamová, Jan Zuna
2020-06-29

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Markus Pfirrmann, Anna Turkina, Tomasz Sacha, Perttu Koskenvesa, Hele Everaus, Edgar Faber, Daniela Žáčková
2020-10-06

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Hana Klamová, Daniela Žáčková
2020-12-25

Evaluation of two CE-IVD tests for <i>BCR-ABL1</i> transcript monitoring of chronic myeloid leukemia patients

Adam Folta, Daniela Žáčková, Jiri Mayer, Ivana Jeziskova
2019-12-09

Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex

Michaela Kunova, Silvie Foldynová-Trantírková, Pavel Krejčí
2019-09-14

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Michael Lauseker, Tomasz Sacha, Perttu Koskenvesa, Edgar Faber, Daniela Žáčková
2018-04-25

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective

António Almeida, Giuseppe Saglio
2018-10

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

Daniela Žáčková
2018-08-31

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

Zdenek Racil, Eva Koriťáková, Tomasz Sacha, Hana Klamová, Petr Cetkovský, Edgar Faber, Daniela Žáčková
2016-05-01

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

Veronika Nemethova, Irina Sadovnik, Gregor Eisenwort, Harald Herrmann, Peter Valent, Daniela Žáčková
2014-07-22

BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing

Ivana Jeziskova, Veronika Nemethova, Daniela Žáčková
2014-02-06

Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia.

Daniela Žáčková
2013-05-28

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

Martin Haluzík, Jana Drapalova
2013-08-20

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Hana Klamová, Kateřina Machová Poláková
2013-07-23

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

Ladislav Dušek, Eduard Cmunt, Hana Klamová, Kateřina Machová Poláková
2013-02-28

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

Ladislav Dušek, Eduard Cmunt, Hana Klamová, Kateřina Machová Poláková, Petr Cetkovský
2013-02-01

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

Daniela Žáčková
2012-06-01

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood

Ivana Jeziskova, Daniela Žáčková
2012-08-01

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations

Ivana Jeziskova, Daniela Žáčková
2011-02-15

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Marek Trněný, Kyra Michalová, Hana Klamová, Kateřina Machová Poláková, Petr Cetkovský
2011-09-08

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

Kateřina Machová Poláková, Hana Klamová, Petr Cetkovský
2010-07-01

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

Petr Cetkovský, Daniela Žáčková
2010-05-01

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

Hana Klamová, Petr Cetkovský, Edgar Faber, Daniela Žáčková
2010-12-06

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

Hana Klamová, Kateřina Machová Poláková, Petr Cetkovský
2010-03-01

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction

Ivana Jeziskova, Daniela Žáčková
2009-06-01

Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide

Andrea Janikova, Daniela Žáčková

Human - wd:Q95181015

Welcome to Inventaire

the library of your friends and communities

learn more